Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors

NCT07145255 is registered in ClinicalTrials.gov with MBrace Therapeutics as lead sponsor.

NCT NCT07145255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07145255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors
Lead sponsor
MBrace Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 3, 2025
Completion date
December 30, 2029
Enrollment
150 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colo-rectal cancer, lung cancer (non-small cell), pancreas cancer, duct cell adenocarcinoma, prostate cancer castration-resistant prostate cancer